Molecular data
| Physical form | Lyophilized Powder |
|---|---|
| Available sizes | 120mg |
How it works
-
BPC-157
VEGF Pathway
Vessel formation, tissue granulation and nitric oxide signalling have been measured as endpoints in preclinical models.
- Vessel formation measured
- Tissue granulation scored
- Modulates nitric oxide signaling
-
TB-500
Actin Regulation
Cell migration, cytoskeletal remodelling and fibrotic scarring are measured via the thymosin beta-4 pathway.
- Cell migration measured
- Cytoskeletal remodelling observed
- Fibrotic scarring scored
-
GHK-Cu
Collagen & ECM Remodeling
Type I and III collagen synthesis measured, expression changes reported across 4,000+ genes, and copper delivered to tissue during extracellular matrix turnover.
- Type I & III collagen measured
- Modulates 4,000+ genes
- Delivers copper to tissue
What the research shows
-
Dermal
Dermal Models
GHK-Cu is studied for collagen synthesis; BPC-157 and TB-500 in epithelial and scarring models.
-
Mechanistic
Cytoskeletal & Vascular
TB-500 is characterised for actin remodelling; tendon fibroblast viability is measured for BPC-157; vascularisation endpoints for GHK-Cu.
-
Matrix
Anti-Inflammatory
All three peptides demonstrate anti-inflammatory properties through different mechanisms in animal models.
-
Structural
ECM Remodeling
Extracellular matrix deposition and fibrotic scoring as combined endpoints.
Specification
| Components | GHK-Cu 100mg + BPC-157 10mg + TB-500 10mg |
|---|---|
| Strength | 120mg |
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC-UV (99.89% on lot 377PG1) |
| Testing | Third-party HPLC-UV purity, LC-MS identity, net content per peptide |
| Storage | -20°C for long-term stability |
| Light sensitivity | Protect from direct light at all times |
| Solubility | Water-soluble |
| COA | Included with every order |
| Appearance | Blue lyophilized powder |
| Stability | 24 months from manufacture date when stored properly |
How it's tested
Every lot of GLOW+ released to the catalog carries a third-party certificate of analysis. 1 documented lot is on file for this compound, with reported HPLC purity from 99.89% to 99.89% (mean 99.89%), issued by Freedom Diagnostics. 1 of 1 certificates record identity as confirmed.
- Documented lots
- 1
- Reported purity
- 99.89% to 99.89%
- Mean purity
- 99.89%
- Issuing labs
- Freedom Diagnostics
- 2026-10-10 Lot 377PG1Freedom Diagnostics 99.89% View certificate
Frequently asked questions
What is GLOW+ and what does it contain?
GLOW+ is a research peptide blend of three peptides in one 120 mg vial: 100 mg GHK-Cu (copper peptide), 10 mg BPC-157 (Body Protection Compound) and 10 mg TB-500 (Thymosin Beta-4). Each is characterised on a different pathway: collagen synthesis, vascular, and cell migration respectively.
How is GLOW+ different from GLOW?
Same three peptides, different strength. GLOW+ is a 120 mg vial weighted toward GHK-Cu (100 mg), with 10 mg each of BPC-157 and TB-500. GLOW is the 70 mg vial.
How do the three peptides work together?
In preclinical research, vessel formation (angiogenesis) is measured for BPC-157, cell migration via actin regulation for TB-500, and collagen production plus expression changes across 4,000+ genes for GHK-Cu. The three cover distinct pathways, which is the rationale for combining them.
Is GLOW+ FDA approved?
No. GLOW+ is not approved by the FDA for any medical use. It is sold exclusively for in vitro laboratory research purposes. The individual components have varying levels of preclinical evidence but no completed human clinical trials for the combined blend.
How should GLOW+ be stored?
Store lyophilized (powder) form at -20°C for maximum stability. Protect from direct light at all times and avoid repeated freeze-thaw cycles.
What purity testing is performed?
Every lot is tested by an independent US laboratory: HPLC-UV for purity, LC-MS to confirm the identity of each peptide, and net content per peptide. The current lot (377PG1) reads 99.89% purity with GHK-Cu 95.78 mg, BPC-157 10.43 mg and Thymosin Beta-4 9.85 mg per vial. The certificate is linked on this page.
What is the research evidence for this blend?
The rationale is based on individual component research in preclinical models. The combined blend has not been characterised as a single formulation. Complementarity is inferred from mechanism.
Related monographs
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.